BioSpace News Archive

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the use of the ThinPrep ® Pap Test™ PreservCyt ® Solution vial as an approved sample type for its B

Company will initially focus on developing first-in-class mRNA therapeutics for oncology indications and forging collaborations with biotech and pharma companies

MONTREAL, Sept. 23, 2020 /PRNewswire/ - Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it will report its financial results and highlights for the third quarter ended July 31, 2020 on Tuesday September 29, 2020 after market close.

Evergreen Theragnostics, Inc., a radiopharmaceutical Contract Development and Manufacturing Organization, celebrated the groundbreaking for its new manufacturing facility in Springfield, New Jersey.

EBAMed SA, a medical technology company based in Geneva, Switzerland, has been awarded EUR 2.4 million in a non-dilutive grant by the Enhanced European Innovation Council to develop its cardiac motion management product for the non-invasive treatment of heart arrhythmias.

Uterine fibroid embolization is a minimally invasive treatment used to treat fibroid tumors in the uterus.

The global pharmerging market is experiencing a significant rise, especially in the emerging economies across the world.

Oncology is a branch of science that investigates cancer cells. The oncology devices market comprises medical devices that help in the diagnosing and treating of cancer diseases.

A handful of international and local manufacturers with limited shares dominate the global diabetic neuropathy market.

The demand in the global market for constipation treatment is projected to increment at a healthy CAGR of 7.1% during the forecast period of 2017 to 2025.